
    
      This study is a multi-center, randomized, placebo and positive controlled phase IIa
      proof-of-concept study to evaluate the effect of single-dose TPN171H tablets on acute
      hemodynamic parameters in patients with pulmonary arterial hypertension.The trial is expected
      to include 60 patients, divided into 6 groups, according to 1:1:1:1:1:1 into the placebo
      group and the test drugs 2.5mg, 5mg, 10mg group, tadalafil tablets 20mg, 40mg group, each
      group 10 cases. During the screening period, the tube placement period, and the observation
      period, the patients will conduct various inspections and evaluation observations as
      required.

      The Swan-Ganz floating catheter and echocardiography were used to evaluate the efficacy of
      TPN171H; PK parameters: including Tmax, Cmax, AUC0-t , t1/2,CL/F, Vz/F, Î»z; Safety evaluation
      indicators include: vital signs, physical examination, laboratory examination (blood routine,
      blood biochemistry, blood gas analysis), 12-lead ECG, adverse events.
    
  